Dec. 2025 – New US patent
River Stone Bio has announced the grant of a new patent, Microbial Cell with Improved in vivo Conversion of Thebaine/Oripavine. . Dec. 2025 - New US patent further strengthens River Stone IP . This patent, covering the company’s uptake transporter technology, is the first grant of a new patent family and gives the company protection on its unique approach to bioconversion across a range of products. .River RiverStone Biotech - Dec. 2025...
Nov. 2025 – Production of nororipavine
Yeast based N-demethylation for the production of nororipavine in fed-batch or continuous cultivation . In a groundbreaking paper published in Bioresource Technology researchers of University of Melbourne and River Stone it is shown that optimized insect-derived N-demethylases of cytochrome P450 origin can efficiently convert the natural opioid oripavine to the much sought after chemical intermediate nororipavine. With the opioid epidemic ravishing the world cheaper drugs for countering overdose deaths and for treating addiction, access to an affordable supply of the ideal drug precursor nororipavine will be crucial. Using the methodology detailed in the paper, not only can the drugs in question be...
Oct. 2025 – Attending CPHI 2025
River Stone will be attending CPHI in Frankfurt next week - october 2025 . RSB is dedicated to providing life changing APIs and formulations via innovative production methods that blend synthetic biology and chemistry processes. In the first instance RSB is pleased to be able to make a meaningful contribution to the important Opioid Dependence/Substance Abuse Prevention programs around the world. River Stone works with a small number of global providers to establish a virtual cross-functional operation to enable its API offering and is looking to strengthen its network of potential partners and customers. . . ...